Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2009-02-12
2011-10-25
Graser, Jennifer (Department: 1645)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S204100, C424S243100
Reexamination Certificate
active
08043613
ABSTRACT:
The present invention relates to a novel bacteriophage, more precisely a Podoviridae bacteriophage having killing activity specific toStaphylococcus aureuswhich is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused byStaphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage as an active ingredient.
REFERENCES:
patent: 6056955 (2000-05-01), Fischetti
patent: 6121036 (2000-09-01), Ghanbari
patent: 2003/0152594 (2003-08-01), Pillich
patent: 2005/0260171 (2005-11-01), Ghanbari et al.
patent: 2010/0203180 (2010-08-01), Yoon et al.
patent: 2010/0254950 (2010-10-01), Yoon et al.
patent: 2007-82358 (2007-08-01), None
patent: 10-2009-0017862 (2009-02-01), None
patent: 2007-82357 (2009-02-01), None
patent: WO 03/067991 (2003-08-01), None
patent: WO 2004/062677 (2004-07-01), None
patent: WO 2006/063176 (2006-06-01), None
patent: WO 2007/148919 (2007-12-01), None
patent: WO 2009/035303 (2009-03-01), None
patent: WO 2009/035303 (2010-03-01), None
International Search Report issued Mar. 20, 2009 for WO 2009/035303 published on Mar. 19, 2009 (Application No. PCT/KR2008/005434 filed on Sep. 12, 2008) (Inventors—Yoon et al., Applicant—Intron Biotechnology, Inc.).
Written Opinion issued Mar. 20, 2009 for WO 2009/035303 published on Mar. 19, 2009 (Application No. PCT/KR2008/005434 filed on Sep. 12, 2008) (Inventors—Yoon et al., Applicant—Intron Biotechnology, Inc.).
International Preliminary Report on Patentability issued Mar. 16, 2010 for WO 2009/035303 published on Mar. 19, 2009 (Application No. PCT/KR2008/005434 filed on Sep. 12, 2008) (Inventors—Yoon et al., Applicant—Intron Biotechnology, Inc.).
Accession No: KACC 9700IP,Staphloccal bacteriophage, 2007.
Accession No: KCTC 11152BP,Escherichia colipBAD;;Lysin, 2007.
Accession No: KCTC 11151BP, pBAD-TOPO-SALI, 2007.
Accession No: KCTC 11153BP, SAP1 bacteriophage, 2007.
Accession No: KCTC 11154BP, SAP2 bacteriophage, 2007.
Arciola CR, Baldassarri L, Montanaro L, (2001) Presence of IcaA and IcaD genes and slime production in a collection of staphylococcal strains from catheter-associated infections, J. Clin Microbiol. 39(6):2151-2156.
Arciola CR, Montanaro L, Baldassarri L, Borsetti E, Cavedagna D, Donati E, (1999) Slime production by Staphylococcal isolated from prosthesis-associated infections, New Microbiol. 22(4):337-341.
Cisani G, Varaldo PE, Grazi G, Soro O, (1982) High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme, Antimicrob Agents Chemother. 21(4):531-535.
Costerton JW, Lewandowski Z, DeBeer D, Caldwell D, Korber D, James G, (1994) Biofilms, the customized microniche, J Bacteriol, 176(8):2137-2142.
Cramton SE, Gerke C, Schnell NF, Nichols WW, Götz F, (1999) The intercellular adhesion (ica) locus is present inStaphylococcus aureusand is required for biofilm formation, Infect Immun, 67(10):5424-5433.
Graham S, Coote PJ, (2007) Potent, synergistic inhibition ofStaphylococcus aureusupon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. J Antimicrob Chemother, 59(4):759-762.
Gründling A, Missiakas DM, Schneewind O, (2006)Staphylococcus aureusmutants with increased lysostaphin resistance, J Bacteriol, 188(17): 6286-6297.
Kusoma C, Jadanova A, Chanturiya T, Kobai-Kun JF, (2007) Lysostaphin-resistant variants ofStaphylococcus aureusdemonstrate reduced fitness in vitro and in vivo. Antimicrob Agents Chemother. 51(2): 475-482.
Mah TF, O'Toole GA, (2001) Mechanisms of biofilm resistance to antimicrobial agents, Trends Microbiol, 9(1): 34-39.
McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Döring G, Lee JC, Goldmann DA, Pier GB, (1999) Broadly protective vaccine forStaphylococcus aureusbased on an in vivo-expressed antigen, 284(5419): 1523-1527.
O'Gara JP, Humphreys H. (2001)Staphylococcus epidermidisbiofilms; importance and implications, J Med Microbiol, 50(7): 582-587.
Resch A, Fehrenbacher B, Eisele K, Schaller M, Götz F, (2005) Phage release from biofilm and planktonicStaphylococcus aureuscells. FEMS Microbiol Lett. 252(1): 89-96.
Sass P, Bierbaum G, (2007) Lytic activity of recombinant bacteriophage phil1 and phil2 endolysins on whole cells and biofilms ofStaphylococcus aureus, Appl Environ Microbiol, 73(1): 347-352.
Schuch R, Nelson D, Fischetti VA, (2002) A bacteriolytic agent that detects and kills Bacillus anthracis, Nature, 418(6900): 884-889.
Severance PJ, Kauffman CA, Sheagren JN, (1980) Rapid identification ofStaphylococcus aureusby using lysostaphin sensitivity, J Clin Microbiol, 11(6): 724-727.
Vybiral D, Takác M, Loessner M, Witte A, von Absen U, Bläsi U. (2003) Complete nucleotide sequence and molecular characterization of two lyticStaphylococcus aureusphages: 44AHJD and P68, FEMS Microbiol Lett, 219(2): 275-283.
Waldvogel FA, (2000) Infections Associated with Indwelling Medical Devices, pp. 55-88, 2000, ASM, Washington, DC.
Preliminary Amendment filed Mar. 12, 2010 for U.S. Patent Application Publication No. 2010/025495 (U.S. Appl. No. 12/677,990 filed on Mar. 12, 2010) (Inventors—Yoon et al.).
Walencka E, Sadowska B, Rózalska S, Hryniewicz W, Rózalska B, (2006)Staphylococcus aureusbiofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin, Folia Microbiol (Praha), 51(5): 381-386.
Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF, (2003) Lysostaphin disruptsStaphylococcus aureusandStaphylococcus epidermidisbiofilms on artificial surfaces, Antimicrob Agents Chemother, 47(11): 3407-3414.
Choi Yunjaie
Jun Sooyoun
Kang Sanghyeon
Lee Seyung
Son Jeesoo
Ballard Spahr LLP
Graser Jennifer
iNtRON Biotechnology Inc.
LandOfFree
Podoviriedae bacteriophage having killing activity specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Podoviriedae bacteriophage having killing activity specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Podoviriedae bacteriophage having killing activity specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4289856